Application of a combined compound medicine in the treatment of persistent infection caused by pathogenic bacteria
Through a combined compound drug of polymyxin and aminoglycoside antibiotics, the problem of difficult to kill nutrient-insensitive retention bacteria in the prior art is solved, and the rapid killing of bacteria and safety is achieved, and it is suitable for a variety of bacterial infections. Treatment of diseases.
Patent Information
- Application Number
- CN202311798173.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-12-26
AI Technical Summary
Existing antibiotic monotherapy or combination drugs are difficult to effectively kill pathogenic bacteria in a state of resident state, especially nutritionally insensitive resident bacteria, which leads to long treatment cycles, repeated attacks and worsening of the disease, and drug resistance mutations.
Using a combination of polymyxin and aminoglycoside antibiotics, it can quickly kill bacteria by destroying bacterial cell membranes within the clinical blood concentration range for a short time, and use it within a safe concentration range to prevent infection recurrence and drug-resistant mutations. The emergence of
It has achieved efficient killing of nutrient-insensitive surviving bacteria, shortened the treatment course, reduced the risk of recurrence of infection, and showed safety on human cells. It is suitable for the treatment of a variety of bacterial infectious diseases.
Smart Images

Figure CN117442739B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to biomedical technology and relates to the use of a combined compound medicine in the treatment of persistent infection caused by pathogenic bacteria, specifically the use of a combined compound medicine of polymyxin and aminoglycoside antibiotics in the treatment of persistent infection caused by pathogenic bacteria. Background Art
[0002] The persistence ability of bacteria causes the failure of nearly half of clinical antibiotic treatments and is the main cause of chronic infection, recurrent attacks and deterioration of the disease. It can also accelerate the generation of resistance mutations, further exacerbating the crisis of antibiotic resistance.
[0003] Although some progress has been made in the past two decades on the mechanism of bacterial persistence, there are still controversies and it has not been fully revealed. According to whether there are sufficient exogenous nutrients in the bacterial culture during antibiotic treatment, the reported in vitro persistence research models can be divided into two categories: (1) "Nutrient-insensitive" persistence. Even under conditions of abundant exogenous nutrients, bacterial cells have extremely strong tolerance to almost all types of bactericidal antibiotics, and do not die even when killed by high-dose antibiotics. This phenomenon is called "Nutrient-insensitive" persistence, which belongs to the true persistence and is the type of persistence that the present invention strives to overcome. (2) "Nutrient-sensitive" persistence / tolerance. This type of state, in which the antibiotics cannot reach the target or cannot produce sufficient reactive oxygen free radicals due to nutrient deficiency in the culture, resulting in very few cell deaths, was mistakenly considered persistence in the past. Its survival phenotype should actually be classified as tolerance according to the definition and mechanism, not true persistence. Most of the "persistence" reported in the literature belongs to this type. This type of model usually involves adding antibiotics directly to the stationary phase culture of bacteria (without fresh exogenous nutrients), or treating bacterial cells with antibiotics while they are starved in saline. The surviving bacteria can often be killed and cleared in large numbers as long as there are sufficient nutrients.
[0004] Clinical anti-infection treatment lacks effective drugs and methods to kill "nutrient-insensitive" persister pathogens. Currently, reports on drug killing of persisters mainly come from the second type of "nutrient-sensitive" persistence / tolerance research model mentioned above. In 2011, the research group of Professor James Collins of the Massachusetts Institute of Technology reported that in wild-type Escherichia coli ( Escherichia coli) directly added glucose, fructose or mannitol to the stationary phase LB liquid culture of gentamicin, which can promote the bactericidal effect of gentamicin, and this effect can be completely inhibited by the proton motive force inhibitor carbonyl cyanide m-chlorophenylhydrazone (CCCP), indicating that the intracellular absorption of gentamicin depends on the proton motive force. Kim Lewis's research group at Northeastern University in the United States reported that the antimicrobial peptide ADEP4 can continuously activate the proteolytic enzyme ClpP, thereby killing Escherichia coli stationary phase cultures in vitro; unfortunately, the clinical trial of this compound failed. In 2023, Professor Fu Xinmiao's team reported that heat treatment of Escherichia coli stationary phase cultures at 55°C for five minutes can promote aminoglycosides to kill stationary phase persister bacteria. This method cannot be used to treat intra-tissue infections because most human cells cannot withstand heat shock. In addition, the proton motive force inhibitor CCCP can be used in combination with high concentrations of aminoglycosides (500 μg / mL), ampicillin or ciprofloxacin to kill bacteria in the plateau phase; however, CCCP is highly toxic to human and animal cells even at lower concentrations and cannot be used clinically. In short, clinically commonly used antibiotic monotherapy cannot achieve good therapeutic effects by killing the persisting bacteria of the infection, and there are no reports that compound antibiotics can effectively kill the persisting bacteria at clinical blood concentrations.
[0005] Aminoglycoside antibiotics alone cannot effectively kill "nutrient-insensitive" persisters. Aminoglycosides are a well-known group of antibiotics with extremely similar structures and bactericidal mechanisms, including different antibiotic molecules with similar functions. Common aminoglycosides mainly include kanamycin, streptomycin, amikacin, tobramycin, gentamycin, netilmicin, etc. These antibiotics generally have no killing effect on "nutrient-insensitive" persisters within the clinical blood concentration range.
[0006] There are no reports on the effect of polymyxin combined with other bactericidal antibiotics on killing persister bacteria. Polymyxin is a well-known group of polypeptide antibiotics with extremely similar molecular structures and bactericidal mechanisms. It has an inhibitory effect on most Gram-negative bacteria. In terms of structure, it usually only differs in the ester acyl group and two amino acids. Its typical clinical drugs are mainly polymyxin B and polymyxin E, which are currently mainly used as second-line antibiotics.
[0007] In summary, finding new molecules or compound formulations of existing antibiotics that can quickly kill persister bacteria is of great significance for clinical anti-infection treatment, especially chronic infections and recurrent bacterial infections, and for improving citizens' health, and it also generates huge economic value in the field of biomedicine. Summary of the invention
[0008] Existing antibiotic monotherapy or combination therapy is usually difficult to kill pathogenic bacteria in a persister state, especially nutrient-insensitive persisters, which often lead to a series of problems such as long treatment cycles, repeated attacks and deterioration of the disease, treatment failure, and drug-resistant mutations. At present, there is no drug that can effectively kill highly persister pathogens within a clinically applicable concentration range. The novel compound drug of polymyxin antibiotics and aminoglycoside antibiotics disclosed for the first time in the present invention can destroy bacterial cell membranes in a short time within a wide range of clinical blood drug concentrations, leading to rapid death of a large number of bacteria, but is safe for human cells. Therefore, it is expected to be applied to the clinical treatment of various acute or chronic infectious diseases caused by persistent pathogenic bacteria, shorten the course of treatment, prevent recurrence of infection, and slow down the generation of drug-resistant mutations.
[0009] The present invention adopts the following technical solution:
[0010] A use of a combined compound medicine in the preparation of a medicine for treating persistent infection caused by pathogenic bacteria, wherein the combined compound medicine comprises polymyxin and aminoglycoside antibiotics.
[0011] A use of a combined compound medicine in the preparation of a pathogenic bacteria retention inhibition drug, wherein the combined compound medicine comprises polymyxin and aminoglycoside antibiotics.
[0012] A combined compound medicine is used in the preparation of a medicine for enhancing the removal of persistent pathogenic bacteria, wherein the combined compound medicine comprises polymyxin and aminoglycoside antibiotics and further comprises other antibacterial agents.
[0013] The combined compound medicine in the present invention exerts an inhibitory effect on the retention of pathogenic bacteria and is safe for human cells. As common sense, so-called safety refers to pharmaceutically recognized safety. The growth and metabolism of human THP-1 cells treated with the composite polymyxin-aminoglycoside antibiotics of the present invention are not significantly different from those of the normal growth control group without antibiotics. However, the existing respiratory chain proton motive force inhibitor CCCP significantly inhibits growth and causes cell death. Therefore, the peak blood concentration of the composite antibiotic of the present invention for sterilization in clinical use is much lower than the above-mentioned test concentration, and it can theoretically ensure safety for human cells.
[0014] Preferably, the pathogenic bacteria are nutrient-insensitive persisters. Even under conditions of abundant exogenous nutrients, bacterial cells have extremely strong tolerance to almost all types of bactericidal antibiotics, and will not die even when killed under high-dose antibiotic conditions. This phenomenon is called "nutrient-insensitive" persistence, which is a true persistence. Clinical anti-infection treatment lacks drugs and means to effectively kill persistent pathogens. At present, the technology for drug killing of persisters is mainly aimed at nutrient-sensitive persistence / tolerance, and there are few medication regimens for nutrient-insensitive persisters. The present invention discloses for the first time a combined compound drug of polymyxin (mucin) and aminoglycoside antibiotics, which can quickly and massively kill inactive metabolic persisters and tolerant bacteria, and the effect is far better than that of a single antibiotic, and the effect of killing bacteria in an active metabolic growth state is also better than that of a single antibiotic. Therefore, it is obvious that it has potential important application value in clinical anti-bacterial infection treatment, and is expected to be used to treat bacterial infections including pneumonia, bloodstream infection, urinary tract infection, respiratory tract infection, intestinal infection, etc., and is also expected to be used for bacterial infection treatment in animals.
[0015] Therefore, the present invention discloses an application of a combined compound medicine in the preparation of an anti-inflammatory or anti-infective medicine, wherein the combined compound medicine comprises polymyxin and an aminoglycoside antibiotic.
[0016] In the present invention, polymyxin antibiotics include polymyxin or its salts, hydrates, and solvates; aminoglycoside antibiotics include aminoglycoside or its salts, hydrates, and solvates.
[0017] In the present invention, aminoglycoside antibiotics are a large class of molecules with similar structures and functions. Aminoglycoside antibiotics include clinically commonly used kanamycin, amikacin, tobramycin, gentamicin, and streptomycin, and also include other aminoglycoside drug molecules with similar structures and functions.
[0018] In the present invention, polymyxins are a large class of molecules with similar structures and functions, including polymyxin B, polymyxin E, and other molecules with similar structures and functions.
[0019] In the present invention, the content of aminoglycoside antibiotics in the combined compound medicine is 0.01-99.9%, preferably 75-99%, more preferably 85-99%, and in terms of weight percentage, it can be 86-99%, 87-99%, 88-99%, 89-99%, 90-99%, 91-99%, 92-99%, 93-99%, 94-99%, 95-99%, 96-99%, 97-99%, 98-99%. The above proportions are calculated based on the total weight of "polymyxin antibiotics and aminoglycoside antibiotics" as 100%, excluding other components such as carriers; if other carrier components are included, the corresponding proportions are calculated by weight.
[0020] In the present invention, the active ingredients of the combined compound medicine are polymyxin antibiotics and aminoglycoside antibiotics, and further, a carrier may be included; as common sense, the active ingredients polymyxin and aminoglycoside antibiotics are present in the same carrier to form a compound medicine, which is called polymyxin-aminoglycoside compound antibiotics.
[0021] In the present invention, the pathogenic bacteria are in the platform culture phase or the exponential growth phase. The polymyxin-aminoglycoside compound antibiotic can not only efficiently kill the persisters of the platform culture, but also efficiently kill the cells in the exponential growth phase, so that their survival level is also reduced by 7 orders of magnitude and the retention level is reduced by 100 times. Regardless of whether the bacterial cells are in a metabolically active state during exponential growth or in a persister state of slow metabolism or stagnant period, the polymyxin-aminoglycoside compound antibiotic can efficiently kill and eliminate them.
[0022] In the present invention, pathogenic bacteria include Gram-negative bacteria and Gram-positive bacteria. The polymyxin-aminoglycoside compound antibiotic of the present invention has a 100-fold decrease in the level of persistence and survival of different clinical isolates of Escherichia coli and Klebsiella pneumoniae selected at random after killing by the compound antibiotic, compared with the amikacin single-drug killing group; for clinical isolates of Pseudomonas aeruginosa and positive bacteria Staphylococcus aureus, the level of persistence and survival is at least 10 times lower. These results show that the ability of polymyxin-aminoglycoside compound antibiotics to eliminate persisters is better than that of existing single antibiotics, and it has universal applicability in Gram-negative and Gram-positive bacteria.
[0023] Compared with the prior art, the present invention has the following advantages:
[0024] (1) The combined drug of polymyxin and aminoglycoside antibiotics disclosed for the first time in the present invention can rapidly and massively kill inactive metabolic persisters, and the effect is far better than that of single antibiotics, and the effect of killing active metabolic growth bacteria is also better than that of single antibiotics; other types of antibiotics combined in clinical concentration range, as well as polymyxin and clinically commonly used beta-lactam or quinolone antibiotics combined in clinical combination, have not been found to have the effect of rapidly killing nutritionally insensitive persisters in large quantities; in the compound drug of the present invention, the combination index of polymyxin B and polymyxin E with aminoglycosides is 0.25 and 0.4 respectively, and has the function of rapidly destroying bacterial cell membranes, while the same concentration of polymyxin or aminoglycoside alone cannot achieve the effect of destroying cell membranes and killing persisters. Therefore, the compound drug of the present invention obviously has potential important application value in clinical anti-bacterial infection treatment, and is expected to be used to treat bacterial infections including but not limited to pneumonia, bloodstream infection, urinary tract infection, respiratory tract infection, intestinal infection, etc., and is also expected to be used to treat bacterial infections in animals.
[0025] (2) The ability of the polymyxin combined with aminoglycoside antibiotics disclosed in the present invention to eliminate bacteria is widely effective in representative Gram-negative bacteria and Gram-positive bacteria. The scope of application in clinical anti-infection treatment and animal treatment is obviously not limited to the representative strains tested in the present invention, but should be applicable to the vast majority of pathogenic bacteria. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Wild type E. coli The survival ability after being killed by different types of bactericidal antibiotics; A is 3 MIC kanamycin (MIC=8 μg / mL), B is 20 MIC ciprofloxacin (MIC=0.03 μg / mL), C is 20 MIC ampicillin (MIC=6 μg / mL), and D is 3 MIC polymyxin B (MIC=0.3 μg / mL).
[0027] Figure 2 for hipA7 The strains had high persistence and survival to different bactericidal antibiotics, with the wild-type strain as the control; A was 3 MIC kanamycin and 3 MIC streptomycin, B was 20 MIC ciprofloxacin and 20 MIC ampicillin, and C was 3 MIC polymyxin B and 3 MIC mitomycin C (MIC=0.8 μg / mL).
[0028] Figure 3 for metG2 The strains have high persistence and survival to different bactericidal antibiotics, with the wild-type strain as the control; A is 3 MIC kanamycin, 20 MIC ciprofloxacin, 20 MIC ampicillin, and B is 3 MIC polymyxin B, 3 MIC mitomycin C.
[0029] Figure 4 for hipA7 The strain has high persistence and survival ability against the combination of different types of antibiotics, and the wild type strain is used as the control; A is 20 MIC ciprofloxacin + 20 MIC ampicillin; B is 20 MIC ciprofloxacin + 3 MIC kanamycin, C is 20 MIC ciprofloxacin + 3 MIC streptomycin, D is 20 MIC ciprofloxacin + 3 MIC polymyxin B, E is 20 MIC ciprofloxacin + 3 MIC polymyxin E, F is 20 MIC ciprofloxacin + 3 MIC mitomycin C, and G is 20 MIC ampicillin + 3MIC kanamycin.
[0030] Figure 5 for metG2The strain has high persistence survival ability against the combination of different types of antibiotics, and the wild type strain is used as the control; A is 20 MIC ciprofloxacin + 20 MIC ampicillin, B is 20 MIC ciprofloxacin + 3 MIC streptomycin, C is 20 MIC ciprofloxacin + 3 MIC polymyxin B, D is 20 MIC ciprofloxacin + 3 MIC polymyxin E, E is 20 MIC ciprofloxacin + 3 MIC mitomycin C, and F is 20 MIC ampicillin + 3 MIC kanamycin.
[0031] Figure 6 The polymyxin B-kanamycin combination drug is highly effective in killing hipA7 For high persister bacteria, A is a combination of kanamycin (final concentration 20 μg / mL)-polymyxin B (0.9 μg / mL), and the control group is treated with 20 μg / mL kanamycin or 0.9 μg / mL polymyxin B as a single drug; B's combination contains 20 μg / mL kanamycin and 0.003, 0.03, 0.3, or 0.6 μg / mL polymyxin B, respectively; or, the combination contains 8 μg / mL kanamycin and 0.45 μg / mL polymyxin B; C's combination antibiotics contain 20 μg / mL kanamycin and 1 μg / mL polymyxin E, and the control group is treated with 20 μg / mL kanamycin or 1 μg / mL polymyxin E as a single drug; D's combination contains 30 μg / mL ampicillin, 0.9 μg / mL polymyxin B, 0.15 μg / mL ciprofloxacin and 0.9 μg / mL polymyxin B, and the control group was treated with 30 μg / mL ampicillin, 0.15 μg / mL ciprofloxacin or 0.9 μg / mL polymyxin B for single-drug killing.
[0032] Figure 7 The polymyxin B-kanamycin combination drug is highly effective in killing metG2 High persister and wild type E. coli Persistent bacteria, where A is E. coli metG2 strains, B was the wild type, and was treated with a combination antibiotic containing 3 MIC polymyxin B and 2.5 MIC kanamycin, while the control group was treated with 2.5 MIC kanamycin and 3 MIC polymyxin B as single drugs.
[0033] Figure 8 The polymyxin B-kanamycin combination drug is highly effective in killing wild-type E. coli For persister bacteria, the experimental group contained a combination antibiotic of 3 MIC polymyxin B and 2.5 MIC kanamycin, while the control group was killed by a single drug.
[0034] Fig. 9 It is a combination of polymyxin B and aminoglycoside antibiotics that effectively kills hipA7 For high persister bacteria, the combination antibiotics in A contained 0.9 μg / mL polymyxin B and 16 μg / mL amikacin, 0.9 μg / mL polymyxin B and 16 μg / mL streptomycin, the combination antibiotics in B contained 0.9 μg / mL polymyxin B and 16 μg / mL tobramycin, the combination antibiotics in C contained 0.9 μg / mL polymyxin B and 12 μg / mL gentamicin, and the concentration of aminoglycoside molecules in the combination antibiotics in D was uniformly 6 μg / mL.
[0035] Fig.10 It is a combination of polymyxin B and aminoglycoside antibiotics that effectively kills metG2 For high persister bacteria, the combination antibiotics of A contained 0.9 μg / mL polymyxin B and 6 μg / mL amikacin, the combination antibiotics of B contained 0.9 μg / mL polymyxin B and 6 μg / mL streptomycin, the combination antibiotics of C contained 0.9 μg / mL polymyxin B and 6 μg / mL tobramycin, and the combination antibiotics of D contained 0.9 μg / mL polymyxin B and 6 μg / mL gentamicin. Single drugs were used as controls.
[0036] Fig.11 It is a combination of polymyxin B and aminoglycoside antibiotics that effectively kills wild-type E. coli The persister bacteria were detected in the following table: the combination antibiotics of A contained 0.9 μg / mL polymyxin B and 6 μg / mL amikacin, the combination antibiotics of B contained 0.9 μg / mL polymyxin B and 6 μg / mL streptomycin, the combination antibiotics of C contained 0.9 μg / mL polymyxin B and 6 μg / mL tobramycin, and the combination antibiotics of D contained 0.9 μg / mL polymyxin B and 12 μg / mL gentamicin. Single drugs were used as controls.
[0037] Fig.12 It is a polymyxin-aminoglycoside combination antibiotic that has a killing effect on clinical pathogenic bacteria persisters, among which A is Klebsiella pneumoniae clinical isolate 9030, B is Klebsiella pneumoniae clinical isolate 9182, C is Escherichia coli clinical isolate 0005, D is Escherichia coli clinical isolate 0011, E is Pseudomonas aeruginosa clinical isolate 1128, and F is Staphylococcus aureus clinical isolate 1115.
[0038] Fig.13 Caused by polymyxin B-kanamycin combination antibiotics hipA7 The cell membrane potential was lost, where A was a combination antibiotic containing 0.9 μg / mL polymyxin B and 20 μg / mL kanamycin, B was 20 μg / mL kanamycin alone, and C was 0.9 μg / mL polymyxin B.
[0039] Fig.14 Caused by polymyxin B-kanamycin combination antibiotics hipA7 The cell membrane was ruptured, with A taking 2 hours and B taking 4 hours.
[0040] Fig.15 Caused by polymyxin B-kanamycin combination antibiotics hipA7 The cell membrane was ruptured, where A was a combination antibiotic containing 0.9 μg / mL polymyxin B and 20 μg / mL kanamycin, B was 20 μg / mL kanamycin alone, and C was 0.9 μg / mL polymyxin B.
[0041] Fig.16 To evaluate the safety of polymyxin-aminoglycoside combination antibiotics on human cells. DETAILED DESCRIPTION
[0042] The present invention discloses for the first time a combined compound of polymyxin antibiotics and aminoglycoside antibiotics for inhibiting and killing pathogenic bacteria, especially for preparing a drug for treating persistent infection of pathogenic bacteria, especially, the pathogenic bacteria are "nutrient-insensitive" persisters. Among them, polymyxin antibiotics include polymyxin or its salts, hydrates, solvates; aminoglycoside antibiotics include aminoglycoside or its salts, hydrates, solvates.
[0043] In the present invention, the active ingredients of the drug are polymyxin antibiotics and aminoglycoside antibiotics, and further include a carrier.
[0044] In view of the fact that polymyxins are a large class of molecules with similar structures and functions, the polymyxin component range of the combined compound drug disclosed in the present invention is not limited to polymyxin B and polymyxin E, but also includes other molecules with similar structures and functions. The content of polymyxin antibiotics in the finished polymyxin-aminoglycoside compound antibiotics accounts for 0.001 to 95%, so that its applicable concentration range in the bactericidal process reaches 0.001 to 200 μg / mL.
[0045] In view of the fact that aminoglycoside antibiotics are a large class of molecules with similar structures and functions, the scope of combined compound drugs disclosed in the present invention is not limited to the clinically commonly used kanamycin, amikacin, tobramycin, gentamicin, streptomycin, and netilmicin, but should also include other aminoglycoside drug molecules with similar structures and functions. The content of aminoglycosides in the finished compound medicine accounts for 0.01 to 99.5%, so that the applicable concentration range in the bactericidal process reaches 0.01 to 200 μg / mL.
[0046] The above two proportions (content ratio) are calculated based on the total weight of "polymyxin antibiotics and aminoglycoside antibiotics" as 100%, excluding other ingredients such as carriers; if other carrier ingredients are included, they will be calculated in equal proportions by weight.
[0047] As a general rule, the term salt is a pharmaceutically acceptable salt, which refers to a disclosed compound or derivative modified by preparing an acid or base salt thereof. Examples of pharmaceutically acceptable salts include: inorganic or organic acid salts of basic groups such as amines, alkali metal or organic salts of acidic groups such as carboxylic acids, conventional non-toxic salts or quaternary ammonium salts. Conventional non-toxic salts include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid and nitric acid; or salts prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid and isethionic acid. Pharmaceutically acceptable salts can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. In some cases, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in water or in an organic solvent or in a mixture of the two; preferred organic solvents are ether, ethyl acetate, ethanol, isopropanol or acetonitrile. As a general rule, active ingredients include all pharmaceutically acceptable salts, all hydrates and / or solvates of the compounds. Certain functional groups, such as hydroxyl, amino and the like, form complexes and / or coordination compounds with water and / or various solvents in various physical forms of the compounds.
[0048] As common sense, the term carrier is a pharmaceutically acceptable carrier, which is recognized in the art and refers to a pharmaceutically acceptable material, composition or vehicle such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, which participates in carrying or transporting the active ingredient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic compatible substances used in pharmaceutical formulations.
[0049] The administration mode of the combined compound of the present invention is not limited, including oral, intravenous, intramuscular, subcutaneous, transdermal, inhalation, oral, ocular, sublingual, vaginal, rectal, etc. The combined compound of the present invention can be administered in a unit dosage form and / or preparation containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Exemplary forms of oral administration include tablets, capsules, elixirs, syrups, etc. External routes include intravenous, intraarterial, intraperitoneal, epidural, intraurethral, intrasternal, intramuscular and subcutaneous, and any other parenteral administration routes recognized in the art. Administration methods include needle (including microneedle) syringes, needleless syringes and infusion techniques, as well as any other parenteral administration methods recognized in the art. Parenteral preparations are usually aqueous solutions, which may contain excipients such as salts, carbohydrates and buffers, and may also be formulated into sterile non-aqueous solutions or dry forms for use in combination with suitable vehicles (e.g., sterile pyrogen-free water). The preparation of parenteral formulations under sterile conditions, for example, by lyophilization, can readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
[0050] The dosage of the combined drug of the present invention is conventional technology and can be selected according to the method of administration, the condition to be treated, the severity of the condition, whether the condition is to be treated or prevented, and the age, weight and health of the person to be treated. In the present invention, the co-administration of polymyxin and aminoglycoside antibiotics can be carried out simultaneously by any suitable means, which is different from the existing sequential, separate or single pharmaceutical preparation administration.
[0051] The specific drugs used in the present invention are existing products, the specific preparation and experimental methods are conventional techniques, the testing is the existing laboratory technology, the test strains are mainly commercially available standard strains, and the clinical isolates used individually are infectious bacterial isolates available in any hospital.
[0052] The proportion of persister cells in bacterial cultures is usually higher during the nutrient-deficient plateau phase. E. coli) To test the retention capacity of most bactericidal antibiotics, the BW25113 standard strain of Escherichia coli K12 background was cultured in commercial conventional LB liquid culture medium at 37°C to the stationary phase, and then inoculated into fresh LB liquid culture medium containing multiple minimum inhibitory concentration (MIC) antibiotics at a ratio of 1:20 for killing. After treatment for different time periods, samples were taken and centrifuged twice to remove residual antibiotics. After ten-fold gradient dilution in physiological saline, the plates were spread on LB agar plates without antibiotics. After two days of culture, the number of surviving colonies (Colony forming unit, CFU) was counted, and the initial CFU before drug addition was used as the control to calculate the survival rate and retention level of bacteria. This is a conventional experimental method, and the test of other bacteria can refer to this method. The antibiotics used are classic bactericidal antibiotics, including: β-lactams (blocking cell wall synthesis, such as ampicillin), fluoroquinolones (causing double-strand DNA breaks, such as ciprofloxacin), aminoglycosides (acting on ribosomes, causing protein translation errors, such as kanamycin), polymyxins (interfering with cell membrane function, such as polymyxin B), and mitomycins (causing double-strand breaks through GC bridges between DNA chains, such as mitomycin C); the drug dosage adopts the concentration that can kill sensitive bacteria, usually a multiple of the well-known MIC, and the specific concentration can be calculated based on the MIC and the multiple.
[0053] Fluorescence microscopy and flow cytometry are used to detect fluorescent substance signals associated with bacterial cells according to standard procedures and detection methods of instruments or reagents.
[0054] The above is the general method of the bacterial experiment of the present invention, and is also a common analytical method in the literature for analyzing the bacterial retention level. The antibiotics used in the present invention are all commonly used antibiotics in clinical practice; the experimental results show that for the persisting bacteria, the existing antibiotic monotherapy has no good bactericidal effect, and there is no report on the compound drug treatment of persisting bacteria.
[0055] 1. High concentrations of antibiotics and long-term treatment cannot effectively kill the "nutrient-insensitive" persisters in the wild-type Escherichia coli population.
[0056] A small number of cells in the stationary phase culture population of wild-type Escherichia coli have high persistence capacity. When diluted into nutrient-rich culture medium for killing, even after treatment with high concentrations of bactericidal antibiotics, this small number of cells can survive by persisting to resist the killing of existing common clinical antibiotics, and are therefore called "nutrient-insensitive" persisters.
[0057] wild type E. coliWhen BW25113 plateau cultures were treated with kanamycin (24 μg / mL, 3 MIC) for 10 h, which exceeded the peak plasma concentration (20 μg / mL), the viability decreased 100,000-fold, and the persister survival level was maintained at 0.001%. Similarly, when treated with ciprofloxacin (0.6 μg / mL, 20 MIC), ampicillin (120 μg / mL, 20 MIC), or polymyxin B (0.9 μg / mL, 3 MIC) for 10 h, the persister survival level of the cultures was 0.001% (see Figure 1 ). This result shows that the wild-type E. coli About one in one hundred thousand cells in the stationary phase culture are in a "nutrient-insensitive" persistence state. When nutrients are present, they survive by persistence after being treated with different types of clinically commonly used bactericidal antibiotics at high concentrations and for a long time, and can resume growth and reproduction after the antibiotics are withdrawn.
[0058] The vast majority of cells in the stationary phase of E. coli culture are in a "nutrient-sensitive" persister / tolerant state. Unlike the small number of "nutrient-insensitive" persisters mentioned above, E. coli Most of the cells in the stationary phase culture of BW25113 showed very little death when some key nutrients were missing or completely missing without the addition of exogenous nutrients, making it impossible for antibiotics to reach the target or produce sufficient reactive oxygen free radicals; however, when diluted into nutrient-rich medium and treated with antibiotics, the stationary phase culture could be killed in large quantities and quickly by various bactericidal antibiotics commonly used in clinical practice (see Figure 1 Most of these cells that survive nutrient starvation but are killed when external nutrients are present have been mistakenly considered persisters in the past, and their survival phenotypic characteristics should actually be classified as tolerance by definition, and do not belong to true persistence. Therefore, the persistence referred to in the present invention hereinafter generally refers to "nutrient-insensitive" persistence.
[0059] Figure 1 Wild type E. coli The ability to survive after being killed by different types of bactericidal antibiotics, where A is E. coliThe stationary phase culture of the wild-type strain BW25113 was inoculated into fresh LB liquid medium at a ratio of 1:20, and 3 MIC kanamycin (MIC=8 μg / mL) was immediately added. The culture was shaken at 37 ℃ and 160 rpm for 10 h. Samples were taken at different time points, washed to remove the drug, diluted tenfold in normal saline, and spotted on LB agar plates. The number of viable cells (CFU) was determined after culturing for 2 days (d); the conditions of B, C, and D were the same as those of A, and the antibiotics used for killing were 20 MIC ciprofloxacin (MIC=0.03 μg / mL), 20 MIC ampicillin (MIC=6 μg / mL), or 3 MIC polymyxin B (MIC=0.3 μg / mL). Each value was obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation.
[0060] 2. E. coli hipA7 and metG2 The strain has a high level of persistence, and about 10% of the cells in its stationary phase culture can resist killing by a single drug from any of the five major classes of bactericidal antibiotics.
[0061] E.coli hipA7 and metG2 As two typical high-persistent strains, both can be purchased or constructed according to the literature to further evaluate the killing effect of antibiotics on high-persistent cells. hipA7 The strain was obtained through evolutionary screening in 1983 and is the first recognized high-persistence cell strain. It is often used to study the mechanism of persistence formation. The methionyl-tRNA synthetase gene reported in 2012 metG2 The mutant strain was obtained by screening the transposon library and has hipA7 High retention capacity of similar strains.
[0062] hipA7 About 10% of the cells in the stationary phase culture of the strain have strong retention capacity for five types of bactericidal antibiotics and can resist the killing effect of any single antibiotic. hipA7 The survival level of the cells in the stationary phase was maintained at 10% after 10 h of killing in fresh LB medium containing 3 MIC kanamycin, which was higher than that of the wild type. E. coli 10,000 times better, and similarly, hipA7 After killing the plateau cultures with 20 MIC ciprofloxacin, 20 MIC ampicillin, 3 MIC polymyxin B, or 3 MIC mitomycin C, the survival level remained at about 10% (see Figure 2 ). Figure 2 for hipA7 The strain has high persistence to different bactericidal antibiotics, among which A is E.coli hipA7The stationary phase cultures of the strain and the wild-type strain were diluted 1:20 into fresh LB liquid medium, and 3 MIC kanamycin was immediately added. The culture was shaken at 37 °C and 160 rpm for 10 h, and samples were taken at regular intervals. Figure 1 The conditions in A were used to determine the number of viable cells; the conditions in B and C were as follows Figure 1 In Figure A, the antibiotics used for killing were 3 MIC streptomycin, 20 MIC ciprofloxacin, 20 MIC ampicillin, 3 MIC polymyxin B, or 3 MIC mitomycin C (MIC = 0.8 μg / mL). Each value was obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation.
[0063] metG2 About 1-10% of the cells in the stationary phase culture of the strain had strong retention of five types of bactericidal antibiotics. hipA7 similar, metG2 After the cell cultures in the stationary phase were treated with different antibiotics for 10 h, including 20 MIC ciprofloxacin, 20 MIC ampicillin, 3 MIC streptomycin, 3 MIC polymyxin B or 3 MIC mitomycin C, the survival level was maintained at 1-10% ( Figure 3 ). Figure 3 for metG2 The strain has high persistence and survival ability to different bactericidal antibiotics; A and B are E.coli metG2 The stationary phase cultures of the strain and the wild-type strain were inoculated into fresh LB liquid medium at a ratio of 1:20, and 3 MIC kanamycin, 20 MIC ciprofloxacin, 20 MIC ampicillin, 3 MIC polymyxin B or 3 MIC mitomycin C were added, respectively. Figure 1 The cells were cultured under the conditions described in A and the number of surviving cells was determined after different treatment times. Each value was obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation.
[0064] The above results show that E. coli hipA7 and metG2 Compared with the wild-type strain, the level of "nutrient-insensitive" persisters in the stationary phase culture of the strain increased by thousands of times. Even under conditions of abundant exogenous nutrients, any commonly used bactericidal antibiotics in clinical practice (including aminoglycosides and polymyxins) could not effectively kill the persister bacterial cells by single-drug treatment.
[0065] 3. The combination of bactericidal antibiotics cannot effectively kill wild-type E. coli and hipA7 , metG2 Persistent cells of the strain.
[0066] To investigate the effect of combined killing of antibiotics on the viability of persister bacteria, wild-type E. coli and hipA7 , metG2 The stationary phase culture of the strain was treated with an antibiotic for 5 h under conditions of sufficient exogenous nutrients, then the antibiotic was washed away and replaced with another antibiotic of a different target type for another 5 h of killing, and the survival rate was measured.
[0067] hipA7 After the strain culture was killed with 20 MIC ciprofloxacin for 5 hours, it was immediately switched to another target type of antibiotic for further killing, such as 20 MIC ampicillin, 3 MIC kanamycin, 3 MIC streptomycin, 3 MIC polymyxin B / polymyxin E (Colistin), 3 MIC mitomycin C, and the cell survival level was maintained at 3-10%; similarly, hipA7 The culture was pre-killed with 20 MIC ampicillin for 5 h and then with 3 MIC kanamycin for 5 h. The cell survival level was still maintained at 3-10%; see Figure 4 However, wild-type E. coli The cultures were killed by various antibiotic combinations mentioned above, and the retention level was as low as 0.001-0.0001%. Figure 4 for hipA7 The strain has high persistence against the combined killing of different types of antibiotics, and the wild-type strain is the control; A is E.coli hipA7 The stationary phase culture of the strain and the wild-type strain was diluted into fresh LB liquid medium at 1:20, and 20 MIC ciprofloxacin was immediately added. The cells were cultured at 37 °C and 160 rpm with shaking for 5 h. The cells were collected by centrifugation, washed twice to remove the drug, and resuspended in an equal volume of fresh LB medium containing 20 MIC ampicillin. The culture and killing were continued for 5 h. Figure 1 The conditions in A were used to determine the number of viable cells; the conditions in B to G were the same as in A, except that the antibiotic types and concentrations of different killing combinations were 20 MIC ciprofloxacin, 3 MIC kanamycin, 3 MIC streptomycin, 3 MIC polymyxin B / E, 3 MIC mitomycin C, and 20 MIC ampicillin. Each value was obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation.
[0068] metG2 After the strain culture was treated with different antibiotics, the combination of killing showed the same hipA7 For example, after killing with 20 MIC ciprofloxacin for 5 h, the cells were switched to 20 MIC ampicillin, 3 MIC streptomycin or 3 MIC polymyxin B for another 5 h, and the cell survival level was maintained at 1-5% ( Figure 5). Figure 5 for metG2 The strain has high persistence against the combined killing of different types of antibiotics, and the wild-type strain is the control; A is E. coli metG2 The stationary phase culture of the strain and the wild-type strain was diluted into fresh LB liquid medium at 1:20, and 20MIC ciprofloxacin was immediately added. The cells were cultured at 37 °C and 160 rpm with shaking for 5 h. The cells were collected by centrifugation, washed twice to remove the drug, and resuspended in an equal volume of fresh LB medium containing 20MIC ampicillin. The culture and killing were continued for 5 h. Figure 1 The number of viable cells was determined under the conditions in A; the conditions in B to F were the same as in A, and the antibiotic types and concentrations of different killing combinations were 20 MIC ciprofloxacin, 3 MIC kanamycin, 3 MIC streptomycin, 3 MIC polymyxin B / E, 3 MIC mitomycin C, and 20 MIC ampicillin, respectively. Each value was obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation.
[0069] These results indicate that persistence, which is broadly resistant to all bactericidal antibiotics (especially nutrient-insensitive persistence), exists in cultures of different strains, such as the wild type E. coli and hipA7 , metG2 Mutant strains, this type of pan-antibiotic persisting bacterial cells are likely to have a persistence and resistance ability similar to that of spores or spores, and have super resistance to almost all types of bactericidal antibiotics commonly found on the market. They can still survive after long-term treatment with high-concentration antibiotics, and can survive even when they are killed by a combination of antibiotics targeting different target types in turn due to persistence. This is a difficult problem that has not been overcome in clinical anti-infection treatment so far. Embodiment 1
[0070] The combination drug of polymyxin and aminoglycoside antibiotics can effectively kill various persistent bacteria within the clinical blood concentration range.
[0071] Under the experimental conditions of clinical blood drug concentration or lower than clinical blood drug concentration, different antibiotic compounds obtained by combining polymyxin with various aminoglycoside molecules can quickly and massively kill various persister bacteria tested, achieving the purpose of rapidly and massively eliminating persister bacteria in a short period of time. It is known that the peak clinical blood drug concentration of kanamycin is about 18-20 μg / mL, which is a good concentration for E. coli The MIC of BW25113 is approximately 2.5; the clinical guidance dose of polymyxin is 2 mg / kg, and the average blood concentration is approximately 2.8 μg / mL (range 0.68-4.88 μg / mL).
[0072] The polymyxin-aminoglycoside compound antibiotics used in the experiment are pre-mixed into compound medicines with different ratios before use, so that the synergistic effect of the two drug components is optimal; for in vitro experiments, the two drugs can also be added to the same culture at a certain ratio to kill. In the drug concentrations involved in the embodiments, mL is calculated according to the culture medium.
[0073] See also Figure 6 , a combination of polymyxin B and kanamycin that effectively kills hipA7 Highly persisting bacteria, where A is E.coli hipA7 The stationary phase culture of the strain was diluted into fresh LB medium at 1:20, and a combination of kanamycin (final concentration 20 μg / mL) and polymyxin B (0.9 μg / mL) was immediately added. The control group was treated with 20 μg / mL kanamycin or 0.9 μg / mL polymyxin B alone, and cultured at 37 °C and 160 rpm for 10 h. Figure 1 The conditions in A were used to measure the number of surviving cells at different killing times; the conditions in B were the same as in A, except that the kanamycin in the compound drug was 20 μg / mL and the polymyxin B was 0.003, 0.03, 0.3 or 0.6 μg / mL, respectively; or, the compound contained 8 μg / mL kanamycin and 0.45 μg / mL polymyxin B; the conditions in C were the same as in A, except that the compound antibiotic contained 20 μg / mL kanamycin and 1 μg / mL polymyxin E (also known as Christian), and the control group was killed with 20 μg / mL kanamycin or 1 μg / mL polymyxin E; the conditions in D were the same as in A, except that the compound drug contained 30 μg / mL ampicillin and 0.9 μg / mL polymyxin B, 0.15 μg / mL ciprofloxacin and 0.9 μg / mL polymyxin B, respectively, and the control group was killed with 30 μg / mL ampicillin, 0.15 Single-drug killing was performed with 0.1 μg / mL ciprofloxacin or 0.9 μg / mL polymyxin B. Each value was obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation. hipA7 The stationary phase culture of the strain was diluted into fresh LB medium, and a combination of polymyxin B and kanamycin was immediately added for killing, with concentrations of 0.9 μg / mL (3 MIC) and 20 μg / mL (2.5 MIC), respectively; hipA7 The survival rate of persisters decreased rapidly by 7 orders of magnitude, with the persistence level as low as 10 -7 ~10 -8 Compared with the control group treated with 2.5 MIC kanamycin or 3 MIC polymyxin B alone (retained survival level 5-10%), it was reduced by at least one million times; 2.5 MIC kanamycin was combined with lower concentrations of polymyxin B (0.01, 0.1, 1 and 2 MIC) respectively. hipA7 The persistence level of the bacteria was reduced by 10 to 10,000 times; similarly, the concentrations of polymyxin B and kanamycin in the combination drug were reduced to 1.5 MIC (0.45 μg / mL) and 1 MIC (8 μg / mL), hipA7 The retention level of polymyxin B decreased by more than 10 times. Therefore, the combination of polymyxin B and kanamycin can kill bacteria rapidly and in large quantities over a wide range of clinical blood drug concentrations. hipA7 Highly persisting bacteria. The combination of polymyxin E and kanamycin can also quickly kill persisting bacteria. 2.5 MIC kanamycin combined with 1.0 μg / mL (10 MIC) polymyxin E, hipA7 The persistence level after killing was reduced by at least 10,000-fold. The combination of polymyxin B and ampicillin or ciprofloxacin was significantly lower than that of the control group after killing with single drugs. hipA7 The retention level did not change significantly and remained at around 5-10%. This result shows that not all combination drugs or any compound drugs can achieve better technical effects than single drugs, especially the combination of polymyxin and β-lactams that destroy cell walls, or quinolone antibiotics that cause DNA breaks, have no synergistic effect in eliminating persister bacteria. It also shows that the phenomenon of polymyxin and aminoglycoside combination drugs synergizing each other and quickly killing persister bacteria is unpredictable.
[0074] To illustrate the bactericidal synergistic effect of polymyxin and aminoglycosides, the conventional method was used to calculate their synergistic index (i.e., partial inhibitory concentration index, abbreviated as FICI, ≤0.5 indicates significant synergistic effect). The FICI value of the combination of kanamycin and polymyxin B was 0.25, and the FICI value of the combination with polymyxin E was 0.4. Therefore, polymyxin and aminoglycoside antibiotics form a compound drug that can not only quickly kill the persisting bacteria, but also reduce the drug concentration required to inhibit bacterial growth through synergistic effects. Embodiment 2
[0075] A combination of polymyxin-aminoglycoside antibiotics that can kill rapidly and in large quantities metG2 High persister and wild type E. coli Low-level persisters.
[0076] See also Figure 7 , a combination of polymyxin B and kanamycin that effectively kills metG2 High persister and wild type E. coli Persistent bacteria, where A is E.coli metG2 strains, B is the wild type; the stationary phase culture of the strain was diluted into fresh LB medium at 1:20, and a compound antibiotic containing 3 MIC polymyxin B and 2.5 MIC kanamycin was immediately added; the control group was treated with 2.5 MIC kanamycin and 3 MIC polymyxin B alone, according to Figure 1 The conditions in Figure A were used to determine the number of surviving cells at different killing times. metG2 After the stationary phase culture of the strain was killed by the combination of polymyxin B and kanamycin, the survival rate dropped rapidly by 7 orders of magnitude and the retention level dropped by 10 2 ~10 6 Similarly, wild type E. coli After being killed by the above-mentioned compound antibiotics, the retention level dropped nearly a thousand times, from 0.001% treated with a single antibiotic to 0.000001%. These results show that for different factors induced and at different survival levels E. coli For persister bacteria, polymyxin-aminoglycoside combination antibiotics can effectively kill them.
[0077] Polymyxin-aminoglycoside combination antibiotics can not only effectively kill persisters in stationary phase cultures, but also effectively kill sensitive cells in exponential growth phases and "nutrient-insensitive" persisters, reducing their survival levels by 7 orders of magnitude and their persistence levels by 100 times, see Figure 8 , a combination of polymyxin B and kanamycin that effectively kills wild-type E. coli Persistent bacteria, wild type E. coli The stationary phase culture was inoculated into fresh LB liquid medium at a ratio of 1:200 and cultured with shaking until the exponential phase (OD 600 =0.3), immediately add a compound antibiotic containing 3 MIC polymyxin B and 2.5 MIC kanamycin, or kill with a single drug, and determine the number of surviving cells at different time points. Each value is obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation. The results show that regardless of whether the bacterial cells are in a metabolically active state during exponential growth or in a persister state during a slow or stagnant metabolic period, the polymyxin-aminoglycoside compound antibiotic can efficiently kill and eliminate them. Among wild-type cells, some cells are nutrient-insensitive persisters, accounting for about 0.001%; these persisters can also be killed by the compound drug of the present invention, reducing the retention level by about 100 times. Embodiment 3
[0078] The combination of polymyxin and various common aminoglycoside molecules has similar high-efficiency killing and clearance capabilities against persistent bacteria.
[0079] After clarifying the synergistic bactericidal function of kanamycin-polymyxin combination antibiotics, the residual bacteria elimination function of other aminoglycoside molecules after polymyxin combination was further determined, including streptomycin, amikacin, tobramycin, and gentamicin. Although the peak concentration of most of these aminoglycosides in the blood can be higher than 16 μg / mL, the concentration used in the test was no higher than 16 μg / mL, and the concentration of polymyxin B was 0.9 μg / mL. In theory, the higher the concentration of these antibiotics, the better the effect of killing bacteria.
[0080] See also Fig. 9 , a combination of polymyxin B and aminoglycoside antibiotics that effectively kills hipA7 Highly persistent bacteria, E.coli hipA7 The stationary phase culture of the strain was diluted into fresh LB medium at 1:20, and antibiotics were immediately added for killing. The compound antibiotics in A contained 0.9 μg / mL polymyxin B and 16 μg / mL amikacin, 0.9 μg / mL polymyxin B and 16 μg / mL streptomycin, the compound antibiotics in B contained 0.9 μg / mL polymyxin B and 16 μg / mL tobramycin, the compound antibiotics in C contained 0.9 μg / mL polymyxin B and 12 μg / mL gentamicin, and the aminoglycoside molecule concentration in the compound antibiotics in D was uniformly 6 μg / mL. The control group was treated with single drug killing according to Figure 1 The number of viable cells at different time points was determined under the conditions of medium A. Each value was obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation. After polymyxin was used in combination with 16 μg / mL streptomycin, amikacin, tobramycin or 12 μg / mL gentamicin, hipA7 The viability of the plateau culture decreased by 10 6 ~10 7 The concentration of aminoglycoside in the above compound antibiotics was reduced to 6 μg / mL. hipA7 The survival level of plateau cultures was as low as 0.001-0.0001%, which was only about one order of magnitude higher than the survival level obtained by killing with a combination drug containing 16 μg / mL aminoglycosides.
[0081] See also Fig.10 , a combination of polymyxin B and aminoglycoside antibiotics that effectively kills metG2 Highly persisting bacteria, among which A to D are E.coli metG2 The conditions for strain culture, drug concentration of compound antibiotics, killing treatment, and survival determination were all referenced Fig. 9 Middle C and Fig. 9In D, each value was obtained from three independent experiments, and the error bars represent the mean ± standard deviation. After polymyxin and 6 μg / mL of the above aminoglycoside compound antibiotics killed the metG2 The survival level of the culture in the stationary phase was reduced to 0.0001−0.00001%; similarly, after killing with the combination of antibiotics, the wild-type E. coli The level of survival also decreased to 0.0001-0.00001%, see Fig.11 , a combination of polymyxin B and aminoglycoside antibiotics that effectively kills wild-type E. coli Persistent bacteria, A to D are wild type E. coli The conditions for BW25113 strain culture, compound antibiotic concentration, killing treatment, and survival determination were all referenced Fig. 9 Middle C and Fig. 9 In D, each value was obtained from at least three independent experiments, and the error bars represent the mean ± standard deviation. In summary, all the common aminoglycoside molecules and polymyxin compound antibiotics in clinical practice have a high efficiency in killing and clearing persister bacteria. Embodiment 4
[0082] Polymyxin-aminoglycoside combination antibiotics have a broad range of persister-killing abilities against both gram-negative and gram-positive bacteria.
[0083] The compound antibiotic of the present invention has a wide range of persistent bacteria removal capabilities against Gram-negative and Gram-positive pathogenic bacteria. Several typical clinical pathogens are selected for killing. Gram-negative bacteria include clinical strains of Escherichia coli, clinical strains of Klebsiella pneumoniae and clinical strains of Pseudomonas aeruginosa, and Gram-positive bacteria are clinical strains of Staphylococcus aureus. The representative compound antibiotic contains 0.9 μg / mL polymyxin B and 16 μg / mL amikacin. Fig.12 , which is a polymyxin-aminoglycoside compound antibiotic that has a killing effect on clinical pathogenic bacteria persisters. The conditions for cell culture, killing treatment, and survival assays were all referenced Figure 1In Figure A, the representative compound antibiotic contains 0.9 μg / mL polymyxin B and 16 μg / mL amikacin, where A is Klebsiella pneumoniae clinical isolate 9030, B is Klebsiella pneumoniae clinical isolate 9182, C is Escherichia coli clinical isolate 0005, D is Escherichia coli clinical isolate 0011, E is Pseudomonas aeruginosa clinical isolate 1128, and F is Staphylococcus aureus clinical isolate 1115; each value is obtained from three independent experiments, and the error bars represent the mean ± standard deviation. The results showed that after the culture of different clinical isolates of Escherichia coli and Klebsiella pneumoniae was killed by compound antibiotics, the retention survival level decreased by 100 to 100,000 times compared with the amikacin single-drug killing group; the retention level of Pseudomonas aeruginosa and Staphylococcus aureus decreased by 10 times after the action of compound antibiotics compared with the single-drug treatment. These results indicate that the ability of polymyxin-aminoglycoside combination antibiotics to eliminate persister bacteria is superior to that of single antibiotics and is universal in both Gram-negative and Gram-positive bacteria. Embodiment 5
[0084] The combination antibiotics containing 0.9 μg / mL polymyxin B and 20 μg / mL kanamycin are representative. hipA7 Measuring cell membrane damage during antibiotic killing in cultures stressed with antibiotics. Fig.13 , caused by polymyxin B-kanamycin combination antibiotics hipA7 The cell membrane potential was lost, where A was a combination antibiotic containing 0.9 μg / mL polymyxin B and 20 μg / mL kanamycin, B was 20 μg / mL kanamycin alone, and C was 0.9 μg / mL polymyxin B. E. coli hipA7 The stationary phase culture of the strain was inoculated into fresh LB liquid medium at a ratio of 1:20, and a compound antibiotic containing a final concentration of 20 μg / mL kanamycin and 0.9 μg / mL polymyxin B was immediately added. Parallel samples were treated with corresponding concentrations of single drugs and cultured at 37°C and 160 rpm for 8 h. A final concentration of 2.5 μM DiSC3(5) was added 10 min before different sampling time points. The drugs and unbound dyes were washed to remove them, and the cell fluorescence intensity was detected by flow cytometry. 100,000 cells were analyzed for each sample. The results of three independent experiments were basically the same, and representative data from any one of the experiments were randomly selected for plotting. During the compound antibiotic treatment, when labeled with the membrane potential characterization fluorescent dye DiSC3(5), the accompanying hipA7 The rapid cell death and rapid increase in DiSC3(5) signal indicate that the cell membrane potential is decreasing rapidly. Even after a long period of time, the killing of cells by kanamycin or polymyxin B alone did not cause a significant increase in the DiSC3(5) fluorescence signal. Propidium iodide (PI) was used to measure cell membrane damage. Fig.14 and Fig.15 , after the polymyxin B-kanamycin combination antibiotics kill, accompanied by hipA7 The cells in the culture died rapidly and the PI fluorescence signal also increased rapidly, indicating that the cell membrane had ruptured. After 2 h of treatment with kanamycin or polymyxin B alone, the PI fluorescence signal did not increase in most cells, and the fluorescence signal could only be detected in very few cells after 4 h.
[0085] Fig.14 Caused by polymyxin B-kanamycin combination antibiotics hipA7 The cell membrane ruptures, where A is 2 hours and B is 4 hours. Fig.12 condition, E. coli hipA7 The stationary culture was diluted to fresh medium and immediately killed by adding polymyxin B-kanamycin combination antibiotics. Parallel samples were treated with single drugs at corresponding concentrations. Samples were taken at 0, 2, and 4 h. PI dye was added at a final concentration of 5 μM 10 min before sampling. After washing with saline to remove drugs and extracellular dyes, the cell fluorescence intensity was detected by flow cytometry. 100,000 cells were analyzed for each sample. The results of three independent experiments were basically the same, and the representative data of one of the experiments were randomly selected for plotting. Fig.15 Caused by polymyxin B-kanamycin combination antibiotics hipA7 Cell membrane rupture, where A is a compound antibiotic containing 0.9 μg / mL polymyxin B and 20 μg / mL kanamycin, B is 20 μg / mL kanamycin alone, and C is 0.9 μg / mL polymyxin B. E. coli hipA7 The parameters and conditions of cell culture, antibiotic killing, PI staining, etc. were all as per Fig.13 The samples at different time points were washed with physiological saline, and the fluorescence intensity of cells was detected at the single-cell level by fluorescence microscopy. The results of three independent experiments were basically the same. Multiple fields of view were analyzed for each sample, and the representative data of one of the experiments were randomly selected for plotting; the percentage data represents the proportion of dead cells containing PI fluorescence to total cells, and 1,000 cells in multiple fields of view were randomly selected for statistical analysis. Embodiment 6
[0086] To evaluate the safety of compound antibiotics on human cells, the final concentrations of the two components in the compound antibiotics were increased to several times the bactericidal concentrations determined above. Representative compound antibiotics contained 6 μg / mL polymyxin B and 80 μg / mL kanamycin or 80 μg / mL amikacin. Their effects on the growth and metabolism of the human cell line THP-1 were investigated. Cell cultures without compound addition were used as blank controls, and CCCP, an inhibitor of respiratory chain proton motive force, was added as a positive control. Fig.16, for the safety assessment of polymyxin-aminoglycoside combination antibiotics on human cells. THP-1 cells were seeded into 48-well plates and cultured at 37 °C in a 5% CO2 incubator for 24 h. At this time, the cell density per well was 4-5×10 5 cell / mL, compound antibiotics or single antibiotics with concentrations higher than blood concentration were added, and the concentrations were 80 μg / mL kanamycin, 80 μg / mL amikacin, and 6 μg / mL polymyxin B. Parallel samples were added with 20 μg / mL CCCP as a control, and the culture was continued for 10 h. CCK-8 reagent was added at different times and the culture was continued for 1 h. The OD was measured with an enzyme reader 450 The results showed that the growth and metabolism of THP-1 cells treated with the above two compound antibiotics were not significantly different from those of the normal growth control group without antibiotics, but CCCP (20 μg / mL) significantly inhibited growth and caused cell death. Therefore, the peak blood concentration of compound antibiotics for sterilization in clinical use is much lower than the concentration of this toxicity test, which can theoretically ensure safety for human cells.
[0087] The prior art has not reported any antibiotics that, whether used alone or in combination, can kill nutrient-insensitive persisters at clinically applicable concentrations. Regardless of the genotype causing the nutrient-insensitive persisters, or the original persistence level (e.g., the wild type is only 0.001%, while the hipA7 / metG2 5-10%), the compound antibiotics of the present invention can effectively kill them; this shows that the compound antibiotics of the present invention have achieved unexpected technical effects.
Claims
1. Use of a combined compound medicine in the preparation of a drug for treating pathogenic bacteria persistence infection or a drug for inhibiting pathogenic bacteria persistence, characterized in that: The combined compound drug includes a polymyxin antibiotic and an aminoglycoside antibiotic; the pathogenic bacteria are nutrient-insensitive persisters, and the pathogenic bacteria are Escherichia coli hipA7 strain and metG2 strain; the polymyxin antibiotic is selected from polymyxin B, polymyxin E or their salts; the aminoglycoside antibiotic is selected from kanamycin, streptomycin, amikacin, tobramycin, gentamicin, netilmicin or their salts.
2. The use according to claim 1, characterized in that: The combined compound medicine is safe for human THP-1 cells.
3. Use of a combined compound medicine in the preparation of a drug for enhancing the removal of persistent pathogenic bacteria, characterized in that: The combined compound drug includes a polymyxin antibiotic and an aminoglycoside antibiotic; the pathogenic bacteria are nutrient-insensitive persisters, and the pathogenic bacteria are Escherichia coli hipA7 strain and metG2 strain; the polymyxin antibiotic is selected from polymyxin B, polymyxin E or their salts; the aminoglycoside antibiotic is selected from kanamycin, streptomycin, amikacin, tobramycin, gentamicin, netilmicin or their salts.
4. The use according to claim 3, characterized in that: The medicament also includes other antibacterial agents.
5. The use according to claim 1 or 3, characterized in that: In the combined compound medicine, the weight content of aminoglycoside antibiotics accounts for 0.01 to 99.5%.
6. Use of a combined compound medicine in the preparation of an anti-infective drug, characterized in that: The combined compound drug is a polymyxin antibiotic and an aminoglycoside antibiotic; the polymyxin antibiotic is selected from polymyxin B, polymyxin E or their salts; the aminoglycoside antibiotic is selected from kanamycin, streptomycin, amikacin, tobramycin, gentamicin, netilmicin or their salts; the infection is infection with Escherichia coli hipA7 strain or metG2 strain.
